Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aetna post-Claritin

This article was originally published in The Tan Sheet

Executive Summary

Aetna's aggressive formulary management steps following OTC switch of Schering-Plough's Claritin have led to 80% decrease in members' use of Rx low- and non-sedating antihistamines, insurer says. After Claritin switched OTC, Aetna moved Schering's Clarinex, Aventis' Allegra, Pfizer's Zyrtec to "non-formulary" status, meaning members of open formulary plan can receive an Rx at the highest tier copay of $30-$35, resulting in no economic incentive for patients to choose Rx products. Aetna also partnered with Wyeth to include Alavert samples in mailings to physicians and members who received an Rx NSA in 2002 (1"The Tan Sheet" Feb. 10, 2002, In Brief). Managed care firm says it is developing a formulary strategy for PPIs following switch of Prilosec (2"The Tan Sheet" June 23, 2003, p. 3)...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS095621

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel